JPWO2025009503A1 - - Google Patents
Info
- Publication number
- JPWO2025009503A1 JPWO2025009503A1 JP2025515752A JP2025515752A JPWO2025009503A1 JP WO2025009503 A1 JPWO2025009503 A1 JP WO2025009503A1 JP 2025515752 A JP2025515752 A JP 2025515752A JP 2025515752 A JP2025515752 A JP 2025515752A JP WO2025009503 A1 JPWO2025009503 A1 JP WO2025009503A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023109588 | 2023-07-03 | ||
| JP2023109588 | 2023-07-03 | ||
| PCT/JP2024/023780 WO2025009503A1 (ja) | 2023-07-03 | 2024-07-01 | 細胞膜透過性を有するペプチドおよびそのスクリーニング方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2025009503A1 true JPWO2025009503A1 (https=) | 2025-01-09 |
| JPWO2025009503A5 JPWO2025009503A5 (https=) | 2025-06-10 |
| JP7723457B2 JP7723457B2 (ja) | 2025-08-14 |
Family
ID=94171533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025515752A Active JP7723457B2 (ja) | 2023-07-03 | 2024-07-01 | 細胞膜透過性を有するペプチドおよびそのスクリーニング方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7723457B2 (https=) |
| WO (1) | WO2025009503A1 (https=) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005013073A (ja) * | 2003-06-25 | 2005-01-20 | Mitsubishi Pharma Corp | 輸送ポリペプチドのスクリーニング方法 |
| WO2006041194A1 (ja) * | 2004-10-15 | 2006-04-20 | Japan Science And Technology Agency | mRNA-ピューロマイシン-タンパク質連結体作製用リンカー |
| JP2009527251A (ja) * | 2006-02-20 | 2009-07-30 | エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション | 細胞膜透過性ペプチド |
| JP2019528693A (ja) * | 2016-09-21 | 2019-10-17 | アマル セラピューティクス エスエー | 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びtlrペプチドアゴニストを含む融合体 |
| WO2022238530A1 (en) * | 2021-05-12 | 2022-11-17 | University Of Copenhagen | Psd-95 inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2548807C2 (ru) * | 2009-05-20 | 2015-04-20 | Торэй Индастриз, Инк. | Пептиды, проникающие в клетку |
| US10736941B2 (en) * | 2015-05-19 | 2020-08-11 | National University Corporation Kumamoto University | Cell membrane-permeating peptide |
| NL2016207B1 (en) * | 2016-02-02 | 2017-08-21 | Stichting Katholieke Univ | Selective cell penetrating peptides. |
| EP3597223A1 (en) | 2018-07-17 | 2020-01-22 | Centre National De La Recherche Scientifique | Peptides for use as cell-penetrating peptides |
| KR102588548B1 (ko) * | 2019-07-16 | 2023-10-16 | 주식회사 젠센 | 자가면역질환 및 염증성질환 펩타이드 치료제 |
| JP7578991B2 (ja) * | 2019-08-28 | 2024-11-07 | 国立研究開発法人理化学研究所 | 細胞膜透過性ベシクル |
-
2024
- 2024-07-01 JP JP2025515752A patent/JP7723457B2/ja active Active
- 2024-07-01 WO PCT/JP2024/023780 patent/WO2025009503A1/ja not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005013073A (ja) * | 2003-06-25 | 2005-01-20 | Mitsubishi Pharma Corp | 輸送ポリペプチドのスクリーニング方法 |
| WO2006041194A1 (ja) * | 2004-10-15 | 2006-04-20 | Japan Science And Technology Agency | mRNA-ピューロマイシン-タンパク質連結体作製用リンカー |
| JP2009527251A (ja) * | 2006-02-20 | 2009-07-30 | エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション | 細胞膜透過性ペプチド |
| JP2019528693A (ja) * | 2016-09-21 | 2019-10-17 | アマル セラピューティクス エスエー | 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びtlrペプチドアゴニストを含む融合体 |
| WO2022238530A1 (en) * | 2021-05-12 | 2022-11-17 | University Of Copenhagen | Psd-95 inhibitors and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025009503A1 (ja) | 2025-01-09 |
| JP7723457B2 (ja) | 2025-08-14 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250314 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250314 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20250314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250314 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250430 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250609 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250715 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250725 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7723457 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |